Enveric Biosciences, Inc.
ENVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,706 | $49,288 | $78,861 | $329,460 |
| - Cash | $2,241 | $2,288 | $17,724 | $17,356 |
| + Debt | $0 | $0 | $64 | $176 |
| Enterprise Value | $465 | $47,000 | $61,201 | $312,280 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$337 | -$408 | -$435 | -$682 |
| % Margin | – | – | – | – |
| EBITDA | -$9,229 | -$16,855 | -$19,517 | -$55,740 |
| % Margin | – | – | – | – |
| Net Income | -$9,575 | -$17 | -$18,504 | -$48,977 |
| % Margin | – | – | – | – |
| EPS Diluted | -228.48 | -97.08 | -156 | -1,244.28 |
| % Growth | -135.4% | 37.8% | 87.5% | – |
| Operating Cash Flow | -$7,726 | -$14,094 | -$17,147 | -$11,458 |
| Capital Expenditures | $0 | -$5 | -$584 | -$865 |
| Free Cash Flow | -$7,726 | -$14,100 | -$17,731 | -$12,322 |